A French startup which uses a novel technology to reconstruct damaged tissue and restore it to its natural state has raised €30m in equity and taken out up to €30m in debt financing, it said today.Tis...
Investment in advanced medical technologies, particularly those addressing tissue repair and synthetic biology, continues to attract significant funding, driven by aging populations and demand for innovative treatments.
This funding round indicates continued investor confidence in medtech and synthetic biology innovations, suggesting potential for breakthroughs in regenerative medicine and expanding market opportunities for advanced biomaterials.
Tissium now possesses substantial capital to further develop and commercialize its tissue reconstruction technology, potentially accelerating its market entry and impact on surgical procedures.
- · Tissium
- · Medtech sector
- · Patients needing tissue repair
- · Investors in life sciences
- · Traditional surgical methods
Tissium will expand its research, development, and commercialization efforts for its tissue reconstruction technology.
Heightened competition and innovation within the regenerative medicine market as new technologies vie for clinical adoption.
Potential for an increased life span and quality of life for individuals with damaged tissues, impacting healthcare costs and demographics.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at Tech.eu